Ju Fu Tang Biotech Holdings Co., Ltd (HKG:8217)

HKG:8217 Financials Overview

Financials in millions HKD. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	37.56	37.56	36.2	35.14	104.6	92.75
Revenue Growth	36.49%	3.74%	3.02%	-66.41%	12.77%	-44.89%
Gross Profit Gross Profit Growth	1.02	1.02	0.98	1.88	-2.88	1.04
Operating Income Operating Income Growth	-6.25	-6.25	-11.25	-4.24	-12.67	-21.5
Net Income Net Income Growth	23.32	23.32	-5.9	-17.43	-9.96	-20.15
Earnings Per Share EPS Growth	0.08	0.08	-0.02	-0.06	-0.03	-0.10
EPS Growth	15.20%	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026
Period Ending	Mar 31, 2026	Mar 31, 2026
Provision of Civil Engineering, Decoration and Renovation Works Provision of Civil Engineering, Decoration and Renovation Works Growth	35.44	35.44
Health Technology Business Health Technology Business Growth	2.11	2.11
Total Total Growth	37.56	37.56

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	60.65	60.65	30.17	26.72	44.22	44.7
Total Debt Total Debt Growth	12	12	14.26	14.26	22.03	55.12
Net Cash (Debt) Net Cash Growth	48.65	48.65	15.91	12.45	22.18	-10.42
Net Cash Growth	21.96%	205.84%	27.77%	-43.87%	-	-
Net Cash Per Share Net Cash Per Share Growth	0.16	0.16	0.05	0.04	0.07	-0.05

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	7.81	7.81	-7.27	3.72	32.23	-19.52
Capital Expenditures CapEx Growth	-	-	-	-	-	-
Free Cash Flow Free Cash Flow Growth	7.81	7.81	-7.27	3.72	32.23	-19.52
Free Cash Flow Growth	-	-	-	-88.45%	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	2.71%	2.71%	2.71%	5.35%	-2.75%	1.12%
Operating Margin	-16.65%	-16.65%	-31.08%	-12.06%	-12.11%	-23.18%
Pretax Margin	62.09%	62.09%	-16.29%	-49.61%	-9.52%	-21.79%
Profit Margin	62.09%	62.09%	-16.30%	-49.61%	-9.53%	-21.72%
FCF Margin	20.80%	20.80%	-20.08%	10.59%	30.81%	-21.04%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 27, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	1.35	3.75	-	-	-	-
P/FCF Ratio	3.98	11.21	-	7.14	1.12	-
PS Ratio	0.83	2.33	1.74	0.76	0.35	0.54

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 27, 2026

Data Sources Report a data error